Anti-Human Amyloid-β (Donanemab) – Fc Muted™ (A535-500ug)

Amyloid-β (Aβ) is a peptide that accumulates in the brains of individuals with Alzheimer’s disease, forming plaques that are a hallmark of the condition. These plaques are believed to contribute to the neurodegenerative processes seen in Alzheimer’s by disrupting cell function and triggering inflammatory responses. Amyloid-β is derived from the amyloid precursor protein (APP) through enzymatic cleavage. The aggregation of Aβ into oligomers and fibrils is a key pathological feature of Alzheimer’s disease, making it a significant target for therapeutic interventions aimed at reducing or preventing plaque formation1,2. LY3002813, known as Donanemab, is a human IgG1, kappa monoclonal antibody designed to target amyloid-beta plaques, which are linked to Alzheimer's disease. By binding to these plaques, Donanemab aims to reduce their accumulation and may slow disease progression. It is primarily used in clinical research and trials, with studies demonstrating its potential to lower amyloid plaque levels and improve cognitive function in early-stage Alzheimer's patient3-7.